Abbott Laboratories

Abbott generates revenue through four main divisions: medical devices (including continuous glucose monitors and heart devices), diagnostics (lab testing and point-of-care systems), nutrition (infant formula brands like Similac and adult supplements like Ensure), and established pharmaceuticals in emerging markets. The company's glucose monitoring system FreeStyle Libre has become a major growth driver, while its diverse portfolio reduces dependence on any single product line.

Abbott offers balanced growth through its mix of stable medical device and nutrition businesses alongside faster-growing diagnostic and glucose monitoring segments. The stock typically trades at a premium P/E ratio reflecting its consistent performance and dividend history. Risks include regulatory challenges for medical devices, competitive pressure in diagnostics, and exposure to emerging market currencies through its pharmaceutical operations. The company has delivered steady earnings growth over the past decade.

In medical devices, Abbott competes with Medtronic (cardiac devices and insulin pumps), Boston Scientific (interventional cardiology), and Dexcom (continuous glucose monitors). For diagnostics, key rivals include Roche and Siemens Healthineers. In infant nutrition, it faces Nestlé and Reckitt Benckiser (Mead Johnson), while competing with Pfizer and Novartis in emerging market pharmaceuticals.

Abbott has paid consecutive quarterly dividends for decades and holds Dividend Aristocrat status, having increased its payout annually for over 50 years. The company maintained this streak even after spinning off AbbVie in 2013. Management targets a payout ratio that allows reinvestment in R&D and acquisitions while returning cash to shareholders, with dividends growing roughly in line with earnings over time.

ABT last closed at $113.60, down 1.65% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $81.97 and a high of $132.03. The current price represents 63% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 32 analysts covering ABT, the consensus rating is Strong Buy — 26 rate it a buy, 6 hold, and 0 sell. The average price target sits at $123.47, implying 9% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Abbott Laboratories generated $43.85B in revenue during fiscal year 2026, with $6.45B reaching the bottom line as net income. The net profit margin of 14.7% is solid for its sector.

ABT trades at a P/E ratio of 39.06 on trailing earnings of $2.70 per share. That's above the S&P 500 historical average, suggesting the market expects above-average earnings growth ahead. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

ABT has been underperforming and remains below where it traded a year ago. Returns by timeframe: +6.97% (1W), +15.06% (1M), +4.58% (3M), +37.60% (6M), -9.08% (1Y), -8.53% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether ABT is outperforming or lagging the broader market.